China Resources Pharmaceutical (03320) announced interim results. Shareholders should account for profit of 2.287 billion yuan, an increase of 5.3% over the previous year

According to the Zhitong Finance App, China Resources Pharmaceutical (03320) announced results for the six months ended June 30, 2026, with revenue of 134.457.6 billion yuan, up 2% year on year; profit attributable to the company's equity shareholders was 2.287 billion yuan, up 5.3% year on year; basic profit per share was 0.35 yuan, and a proposed interim dividend of 0.087 yuan per share.

In the first half of 2026, pharmaceuticals, pharmaceutical distribution, drug retail and the three other major business segments accounted for 16.2%, 79.1%, and 4.7% of revenue, respectively.

During the reporting period, the Group's pharmaceutical business achieved segmental revenue of 24.444.7 billion yuan, a slight decrease of 1.5% over the previous year. The gross margin of the pharmaceutical business was 60.3%, up 1.0 percentage point from the same period last year.

During the reporting period, the Group's pharmaceutical distribution business achieved segmental revenue of 110.994.8 billion yuan, an increase of 2.5% over the previous year. The gross margin of the distribution business was 5.7%, a slight decrease of 0.2 percentage points from the same period last year.

During the reporting period, the Group's pharmaceutical retail business achieved revenue of 6.337.2 billion yuan, an increase of 14.9% over the previous year. Among them, the high-value drug direct delivery (DTP) business achieved revenue of about 4.83 billion yuan, an increase of 28.6% over the previous year. The gross margin of the retail business was 6.3%, an increase of 0.2 percentage points over the same period last year.